SKYRIZI

Product Overview

About SKYRIZI

SKYRIZI is a prescription medication used to treat moderate to severe plaque psoriasis in adults. It contains the active ingredient RISANKIZUMAB, a humanized IgG1 monoclonal antibody that selectively targets the interleukin-23 (IL-23) pathway.

Key Benefits & Uses

• Treatment of moderate to severe plaque psoriasis in adults
• Improvement in symptoms such as redness, scaly patches, and itching associated with psoriasis
• Reduction in the severity of psoriasis lesions and improvement in quality of life

Active Ingredient & Action

RISANKIZUMAB works by binding to the p19 subunit of IL-23, a cytokine involved in the inflammatory response. By inhibiting IL-23, RISANKIZUMAB reduces inflammation and slows down the growth of skin cells, leading to improved symptoms and reduced severity of psoriasis lesions.

Important Notes

SKYRIZI is available by prescription only and should be used under the guidance of a healthcare professional. Common side effects may include upper respiratory tract infections, headache, and fatigue. Patients with a history of inflammatory bowel disease or other inflammatory conditions should use SKYRIZI with caution. Consult the product label or consult with a healthcare professional for more information.